Patents by Inventor Hong Woon Yang

Hong Woon Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS
    Publication number: 20230079833
    Abstract: Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition N associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, multimeric glycomimetic inhibitors of E-selectins, galectin-3, and/or CXCR4 chemokine receptors and their use for treating and/or preventing inflammatory diseases, fibrosis, and cancers are disclosed. Formula (I).
    Type: Application
    Filed: April 21, 2020
    Publication date: March 16, 2023
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Myung-Gi BAEK, Hong-Woon YANG
  • Heterobifunctional inhibitors of E-selectin and galectin-3
    Patent number: 11548908
    Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: January 10, 2023
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Hong-Woon Yang
  • HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3
    Publication number: 20200399301
    Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 24, 2020
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Hong-Woon YANG
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20200291026
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 17, 2020
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Macrocyclic compounds as TRK kinase inhibitors
    Patent number: 10647730
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: May 12, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20190031684
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: February 20, 2018
    Publication date: January 31, 2019
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Macrocyclic compounds as TRK kinase inhibitors
    Patent number: 9902741
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 27, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Macrocyclic compounds as TRK kinase inhibitors
    Patent number: 9840519
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 12, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20170283435
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Macrocyclic compounds as Trk kinase inhibitors
    Patent number: 9750744
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: September 5, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9718796
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: August 1, 2017
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Robert Hershberg, Laurence E. Burgess, Hong Woon Yang
  • Macrocyclic compounds as Trk kinase inhibitors
    Patent number: 9718822
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 1, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9655904
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 23, 2017
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20170114059
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: January 9, 2017
    Publication date: April 27, 2017
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20170112842
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: January 9, 2017
    Publication date: April 27, 2017
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20170107232
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a R3 and R3a are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: November 14, 2016
    Publication date: April 20, 2017
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Macrocyclic compounds as trk kinase inhibitors
    Patent number: 9493476
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: November 15, 2016
    Assignee: Array BioPharma, Inc.
    Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20160129010
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Application
    Filed: August 4, 2015
    Publication date: May 12, 2016
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20150336970
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases
    Type: Application
    Filed: December 18, 2014
    Publication date: November 26, 2015
    Inventors: Steven Wade Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9126940
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 8, 2015
    Assignees: VentiRx Pharmaceuticals, Inc., Array Biopharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang